Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04676503
Other study ID # NTCVAG04_02-2018
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date November 22, 2019
Est. completion date July 21, 2020

Study information

Verified date December 2020
Source NTC srl
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to identify the presence of L. Crispatus in the rectum and vagina after oral administration of BIOVAGINIL by searching for specific DNA of the bacterial strain, to evaluate the tolerability of BIOVAGINIL and evaluate the minimum duration of the oral administration necessary to determine the appearance of L. Crispatus.


Description:

In fertile, premenopausal healthy women, the vaginal ecosystem is dominated by Lactobacillus spp., but a diverse array of other bacteria can be present in much lower numbers. Over 120 species of Lactobacillus have been identified and more than 20 species have been detected in the vagina. Molecular-based techniques have demonstrated that healthy vaginal microflora does not contain high numbers of many different species of Lactobacillus. Rather, one or two lactobacilli from a range of three or four species (mainly L. crispatus and L. iners but also L. jensenii and L. gasseri) are dominant, whereas other species are rare, lower in titer and tend to be novel phylotypes. Vaginitis is defined as a spectrum of conditions that cause vaginal and sometimes vulvar symptoms such as itching, burning, irritation, odor and vaginal discharge. Infection is the most common cause of vaginitis, including bacterial vaginosis (BV), vulvovaginal candidiasis and trichomoniasis. Bacterial vaginosis is a very common microbiological disturbance of the vaginal environment in adult women and is characterized by a depletion of lactobacilli in favor of an overgrowth of anaerobic bacteria. Colonization by L. crispatus or L. jensenii is associated with a lower frequency of bacterial vaginosis, and L. crispatus is strongly correlated with the absence of BV, low pH, negative whiff test, absence of clue cells and normal vaginal discharge. Although antibiotic treatment of BV is strongly recommended, attempts at improving the efficacy of therapy are still a matter of debate. In fact, antimicrobial treatment of urogenital infections is not always effective, and problems remain due to bacterial and yeast resistance, recurrent infections and side effects. Alternative remedies are thus of interest and many studies have provided evidence of the beneficial functions of the human microbiota and prompted the selection of bacterial strains with health-promoting capacities for the treatment of conditions in which the microbiota, or its optimal functioning, is altered. The rationale for the use of probiotics in women is based on the genitourinary regulatory role played by the healthy vaginal microbiota and the need for restoration of this microbial ecosystem after insult. Until today, the most common way of delivering probiotic lactobacilli was the administration of vaginal suppositories.However, this route will no longer be acceptable as products containing probiotics (live microorganisms) are not admissible as medical devices as per European Medical Device Regulation (EU) 2017/245. Oral administration therefore represents an alternative and more patient-friendly concept for the restitution of the normal vaginal microbiota. Indeed, several studies demonstrated the ability of rectal bacteria to move from the intestinal tract to the vagina. Moreover, it was recently demonstrated that the administration of a yoghurt containing Lactobacillus spp. including L.. crispatus in addition to antibiotic treatment may improve recovery rate and symptoms of BV and is well tolerated. It is therefore reasonable to suppose that the oral administration of a food supplement containing an adequate concentration of a strain of L. crispatus, one of the predominant species, in the vaginal microbiota in asymptomatic women, may promote the re-colonization of the vaginal environment. Since this species is so representative and crucial in maintaining a healthy vaginal environment, we believe that it is of utter importance to understand its activity to fully disclose its potential. The aim of this pilot study is to investigate the presence of Lactobacillus crispatus NTCVAG04 in the vagina after oral administration of BIOVAGINIL, a food supplement, as a precondition for the subsequent evaluation of the ability of NTCVAG04 to rebalance the local microbiota and promote healing and/or prevention of recurrences of vaginitis/vaginosis.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date July 21, 2020
Est. primary completion date May 27, 2020
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - Female - Age > 18 years - History of vaginitis/vaginosis - Informed consent Exclusion Criteria: - Pregnancy - Breastfeeding - Need for treatment of vaginitis/vaginosis with any antibiotic drug

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
BIOVAGINIL
Biovaginil is a notified food supplement formulated as 480 mg capsules. Each capsule contains Lactobacillus crispatus NTCVAG04 3 billion and Vitamin A 120 µg.

Locations

Country Name City State
Italy Azienda Ospedaliera Universitaria di Siena - Unità Operativa Semplice Ginecologia Endocrinologica Centro Sterilità di Coppia Siena SI

Sponsors (1)

Lead Sponsor Collaborator
NTC srl

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Positivity for NTCVAG04 in rectal swabs collected at the end of the first treatment cycle. A descriptive statistical analysis will be performed for the rectal swabs for NTCVAG04 At the end of the first cycle ( the cycle is 14 days - Visit 2 - 21st day (± 2) of the menstrual cycle in progress or following enrolment)
Primary Positivity for NTCVAG04 in rectal swabs collected at the end of the second treatment cycle. A descriptive statistical analysis will be performed for the rectal swabs for NTCVAG04 At the end of the second treatment cycles (the cycle is 14 days - Visit 3 - 14th day (± 2) of the next menstrual cycle)
Primary Positivity for NTCVAG04 in vaginal swabs collected at the end of the first treatment cycle. A descriptive statistical analysis will be performed for the vaginal swabs for NTCVAG04 At the end of the first cycle (the cycle is 14 days - Visit 2 - 21st day (± 2) of the menstrual cycle in progress) or following enrolment
Primary Positivity for NTCVAG04 in vaginal swabs collected at the end of the second treatment cycle. A descriptive statistical analysis will be performed for the vaginal swabs for NTCVAG04 At the end of the second treatment cycles (the cycle is 14 days - Visit 3 - 14th day (± 2) of the next menstrual cycle)
Secondary Number of patients with adverse events Analysis of patients that reported an adverse events and analysis of number and type of adverse events. up to 30 days
See also
  Status Clinical Trial Phase
Completed NCT02515656 - Assessment of the Efficacy of POLYGYNAX® in the Empirical Treatment of Infectious Vaginitis Phase 3
Recruiting NCT01420510 - Saginil in vs. Placebo for Gynecologic Oncology Patients Affected by Vaginitis Phase 2/Phase 3
Completed NCT04079218 - Accelerated Genital Tract Aging in HIV: Estradiol Clinical Trial Phase 4
Recruiting NCT05557318 - Using Micro Electro Mechanical Systems to Detect the Air of Vaginal Discharge N/A
Completed NCT01436513 - A Study To Compare The Amount Of Premarin Components That Is Absorbed Into The Blood Of Japanese Healthy Postmenopausal Women Following Oral Administration Of Two Different Tablets Of Premarin Under Fast and Fed Conditions. Phase 1
Completed NCT03585049 - Microscopic Images for the Development of a Rapid Vaginitis Diagnostic Device
Completed NCT02641717 - Validity of Patient-Collected Wet Mounts N/A
Recruiting NCT05587283 - Safety, Tolerability, and Acceptability Study of Intravaginal Administration of LABTHERA-001 Capsules in Healthy Women Phase 1
Not yet recruiting NCT06070454 - Prospective Evaluation of Infectious Vulvovaginitis on Wound Complication Rates After Vulvar Excision for Premalignant Lesions N/A
Completed NCT02365389 - Once Daily In-situ Forming Versus Twice-daily Conventional Metronidazole Vaginal Gels for Treatment of Bacterial Vaginosis Phase 2/Phase 3
Completed NCT01050465 - MedlinePlus Health Prescriptions: Developing a Pragmatic Approach for Clinic Use N/A
Completed NCT05652959 - Real-world Performance and Safety of Cerviron® in the Treatment of Vaginitis
Recruiting NCT02763696 - Establishment of a Sensitive System for Analysis of Child-bearing Women Vaginal Microbiota N/A
Recruiting NCT04574089 - Treatment for Aerobic Vaginitis by Using Bofukang Vaginal Suppository Phase 3
Recruiting NCT04816903 - Gyni™ Study With Leumit Health Services N/A
Completed NCT05670535 - Sjögren and Gynecologic Considerations
Not yet recruiting NCT06438575 - Point of Care Diagnosis of Vaginal Infections N/A
Enrolling by invitation NCT04984460 - Morphological Detection of Liquid-based Thin-layer Film-making Fungi for Fungal Vaginitis in Multiple Hospitals
Completed NCT03151928 - Diagnostic Accuracy By Providers Study
Completed NCT05396261 - a Flexible Wound Dressing for the Management of Genital Skin Conditions N/A